$KGNR
AMJ Global Technology

2021 Q4 Form 10-K Financial Statement

#000147793222001348 Filed on March 11, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $21.33K $49.33K
YoY Change 4384.55%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $21.33K $49.33K
YoY Change 4384.64%
Operating Profit -$49.33K
YoY Change 4384.64%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income -$21.33K -$49.33K
YoY Change 4384.55%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$21.33K -$49.33K
YoY Change 4384.64%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.482K -$3.427K
COMMON SHARES
Basic Shares Outstanding 14.40M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $0.00 $0.00
YoY Change -100.0%
Cash & Equivalents $0.00 $0.00
Short-Term Investments $0.00
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $0.00
Receivables
Other Receivables
Total Short-Term Assets $0.00 $0.00 $0.00
YoY Change -100.0%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $0.00 $0.00 $0.00
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $0.00 $0.00 $0.00
YoY Change -100.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.000K $4.000K
YoY Change -27.27%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.11K $71.11K $21.78K
YoY Change 226.54% 226.49% 5.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $71.11K $71.11K $21.78K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $71.11K $71.11K
YoY Change 226.49%
SHAREHOLDERS EQUITY
Retained Earnings -$1.362M -$1.312M
YoY Change 3.76% 0.08%
Common Stock $14.40K $14.40K
YoY Change 0.0% -1.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$71.11K -$71.11K -$21.78K
YoY Change
Total Liabilities & Shareholders Equity $0.00 $0.00 $0.00
YoY Change -100.0%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$21.33K -$49.33K
YoY Change 4384.64%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$18.15K -$50.83K
YoY Change 1933.24%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.15K $50.83K
YoY Change 1933.24%
NET CHANGE
Cash From Operating Activities -18.15K -$50.83K
Cash From Investing Activities
Cash From Financing Activities 18.15K $50.83K
Net Change In Cash 0.000 $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$18.15K -$50.83K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Auditor Location
AuditorLocation
Farmington, Utah
CY2021Q4 us-gaap Cash
Cash
0 USD
CY2020Q4 us-gaap Cash
Cash
0 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
0 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
0 USD
CY2021Q4 us-gaap Assets
Assets
0 USD
CY2020Q4 us-gaap Assets
Assets
0 USD
CY2021Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4000 USD
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5500 USD
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
67107 USD
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1500 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-71107 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1276084 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1276084 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-49331 USD
CY2020Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
16276 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
71107 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21776 USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14396323 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
14396 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
14396 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1361587 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1312256 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
0 USD
CY2021 us-gaap Revenues
Revenues
0 USD
CY2020 us-gaap Revenues
Revenues
0 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
49331 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1100 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
49331 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
1100 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-49331 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-1100 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-49331 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-1100 USD
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.00
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14396323 shares
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14414405 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-4129 USD
CY2020 kgnr Common Shares Cancelled Amount
CommonSharesCancelledAmount
-16547 USD
CY2020 us-gaap Profit Loss
ProfitLoss
-1100 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-21776 USD
CY2021 us-gaap Profit Loss
ProfitLoss
-49331 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1400 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50831 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2500 USD
CY2021 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
50831 USD
CY2020 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2500 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
50831 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2500 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
0 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2021 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2020 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
0 USD
CY2021 kgnr Common Shares Cancelled For Return Of Equity Investment
CommonSharesCancelledForReturnOfEquityInvestment
0 USD
CY2020 kgnr Common Shares Cancelled For Return Of Equity Investment
CommonSharesCancelledForReturnOfEquityInvestment
16547 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50831 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.</p>
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14396323 shares
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-10360 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-231 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
10360 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
231 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
165414 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
155054 USD
CY2021Q4 kgnr Deferred Tax Asset Valuation Allowances
DeferredTaxAssetValuationAllowances
-165414 USD
CY2020Q4 kgnr Deferred Tax Asset Valuation Allowances
DeferredTaxAssetValuationAllowances
-155054 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
1 pure
CY2021Q4 kgnr Deferred Tax Asset Valuation Allowance
DeferredTaxAssetValuationAllowance
165414 USD
CY2020Q4 kgnr Deferred Tax Asset Valuation Allowance
DeferredTaxAssetValuationAllowance
155054 USD

Files In Submission

Name View Source Status
0001477932-22-001348-index-headers.html Edgar Link pending
0001477932-22-001348-index.html Edgar Link pending
0001477932-22-001348.txt Edgar Link pending
0001477932-22-001348-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kgnr-20211130.xsd Edgar Link pending
kgnr-20211130_cal.xml Edgar Link unprocessable
kgnr-20211130_def.xml Edgar Link unprocessable
kgnr-20211130_lab.xml Edgar Link unprocessable
kgnr-20211130_pre.xml Edgar Link unprocessable
kgnr_10k.htm Edgar Link pending
kgnr_10k_htm.xml Edgar Link completed
kgnr_ex311.htm Edgar Link pending
kgnr_ex312.htm Edgar Link pending
kgnr_ex321.htm Edgar Link pending
kgnr_ex322.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending